Fig. 2. Atypical response to VEGF-targeted therapy in colon cancer Fig. 2. Atypical response to VEGF-targeted therapy in colon cancer. In this 57-year-old woman with metastatic colon cancer, baseline contrast-enhanced CT (A) demonstrates multiple heterogeneous liver metastases. Serum CEA at baseline measured 2049. After 12 weeks of therapy with folinic acid, fluorouracil, oxaliplatin (FOLFOX) and avastin, multiple liver metastases have increased in size but have decreased in density (B), showing greater homogeneity and better defined margins. Serum CEA at time of 12 week follow-up CT measured 1126. Findings at follow-up CT represent response according to CT-morphologic criteria. CEA = carcinoembryonic antigen, VEGF = vascular endothelial growth factor Fig. 2. Atypical response to VEGF-targeted therapy in colon cancer. In this 57-year-old woman with metastatic colon cancer, baseline contrast-enhanced CT (A) demonstrates multiple heterogeneous liver metastases. Serum CEA at baseline measured 2049. After 12 weeks of therapy with folinic acid, fluorouracil, oxaliplatin (FOLFOX) and avastin, multiple liver metastases have . . . Korean J Radiol. 2017 Jan-Feb;18(1):28-41. https://doi.org/10.3348/kjr.2017.18.1.28